Related Experiment Videos
Noble metal complexes in cancer chemotherapy
Advances in Experimental Medicine and Biology
|January 1, 1977
Summary
Platinum coordination complexes, like cis-dichlorodiammineplatinum (II), show promise as anticancer agents. Strategies to mitigate kidney toxicity have improved patient outcomes and allowed for combination chemotherapy against various cancers.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Platinum coordination complexes represent a novel class of anticancer agents with demonstrated efficacy in preclinical and clinical settings.
- Cis-dichlorodiammineplatinum (II) is a leading platinum-based drug currently under experimental clinical investigation for diverse human cancers.
Purpose of the Study:
- To review the current status of platinum coordination complexes as anticancer agents.
- To discuss the clinical applications, toxicity, and potential mechanisms of action of cis-dichlorodiammineplatinum (II).
Main Methods:
- Clinical data review of cis-dichlorodiammineplatinum (II) in cancer treatment.
- Analysis of strategies to manage drug-induced toxicity.
- Exploration of combination chemotherapy regimens and proposed mechanisms of action.
Main Results:
- Cis-dichlorodiammineplatinum (II) exhibits significant activity against various cancers.
- Renal tubular damage is the primary dose-limiting toxicity, effectively managed by hydration and osmotic diuretics.
- Combination chemotherapy has led to improved response rates in multiple cancer types.
Conclusions:
- Platinum coordination complexes, particularly cis-dichlorodiammineplatinum (II), are valuable anticancer agents.
- Management of toxicity is crucial for optimizing therapeutic doses and patient outcomes.
- Further research into the mechanism of action may reveal new therapeutic strategies.